Filing Details
- Accession Number:
- 0001610717-25-000235
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-17 16:10:00
- Reporting Period:
- 2025-06-13
- Filing Date:
- 2025-06-17
- Accepted Time:
- 2025-06-17 16:10:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1501989 | Cytomx Therapeutics Inc. | CTMX | Pharmaceutical Preparations (2834) | 273521219 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1970752 | Marcia Belvin | C/O Cytomx Therapeutics, Inc. 151 Oyster Point Blvd., Ste. 400 South San Francisco CA 94080 | Svp, Chief Scientific Officer | No | No | No | No |
Transaction Summary
| Sold: | 13,884 shares | Avg. Price: $2.69 | Total Value: $37,334.08 |
| Number of Shares After Transactions: | 272,252 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-06-13 | 37,500 | $0.00 | 286,136 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-06-16 | 13,884 | $2.69 | 272,252 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Performance Stock Units | Disposition | 2025-06-13 | 37,500 | $0.00 | 37,500 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- This transaction represents the vesting of performance stock units ("PSUs") initially granted on February 2, 2023.
- Includes 158,958 restricted stock units.
- The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
- Each PSU represented a contingent right to receive one (1) share of common stock upon vesting.
Billionaire Hedge Funds
